Jun 27, 2025, 05:23
Top Biotechs at ASCO: Ying Huang on Carvykti’s 5-Year Data and Expanding CAR-T Therapy in Myeloma
In this episode of Top Biotechs at ASCO, Ying Huang, CEO of Legend Biotech, a leader in cell therapy innovation. Ying shares exciting five-year data for Carvykti (cilta-cel), Legend’s CAR-T therapy for relapsed/refractory multiple myeloma, presented at ASCO 2025.
Legend’s latest results from the CAR-2.1 study show unprecedented outcomes:
- One-third of patients remain progression-free five years after a single infusion.
- Median overall survival extended to 60 months.
- Deep responses with MRD negativity in many patients.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 9, 2025, 11:59
Aug 9, 2025, 11:37
Aug 9, 2025, 11:29
Aug 9, 2025, 11:12
Aug 9, 2025, 10:59
Aug 9, 2025, 10:52
Aug 9, 2025, 10:47